CompletedPhase 2NCT02017444

Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.

Studying Idiopathic intracranial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Birmingham
Principal Investigator
Alexandra Sinclair, MbChb PhD, FNP
University of Birmingham
Intervention
AZD4017(drug)
Enrollment
31 target
Eligibility
18-55 years · FEMALE
Timeline
20142016

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02017444 on ClinicalTrials.gov

Other trials for Idiopathic intracranial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic intracranial hypertension

← Back to all trials